Zosano Pharma (OTCPK:ZSAN.Q) - 주가, 뉴스 및 분석

This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

ZSAN.Q 주식 개요

Zosano Pharma Corporation, a clinical stage biopharmaceutical company, focuses on providing therapeutics and other bioactive molecules to patients suffering from migraine using its transdermal microneedle system.

회사 소개

ZSAN.Q 기본 분석
눈송이 점수
가치 평가	2/6
미래 성장	0/6
과거 실적	0/6
재무 상태	4/6
배당금	0/6

보상

위험 분석

Has less than 1 year of cash runway

Does not have a meaningful market cap ($3K)

Earnings have declined by 5% per year over past 5 years

Makes less than USD$1m in revenue ($659K)

+ 3 더 많은 위험

Zosano Pharma Corporation 경쟁사

Lucira Health

OTCPK:LHDX.Q

US$4.2k

Viveve Medical

OTCPK:VIVE

US$1.1k

ViewRay

OTCPK:VRAY.Q

US$18.3k

American Bio Medica

OTCPK:ABMC

US$4.8k

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 Zosano Pharma
과거 주가
현재 주가	US$0.0007
52주 최고치	US$24.80
52주 최저치	US$0.0001
베타	2.73
11개월 변경	133.33%
3개월 변경 사항	-99.45%
1년 변경 사항	-100.00%
33년 변화	-100.00%
5년 변화	-100.00%
IPO 이후 변화	-100.00%

최근 뉴스 및 업데이트

Recent updates

Can Zosano Pharma (NASDAQ:ZSAN) Afford To Invest In Growth?

Nov 02

Is Zosano Pharma (NASDAQ:ZSAN) Weighed On By Its Debt Load?

Jun 29

Data supports long-term benefit of Zosano's migraine candidate; shares surge 23%

May 26

Zosano Pharma: Early PK+Safety Study In Q3 2021 May Breathe New Life Into This Biotech

Apr 30

Zosano shares rise on migraine treatment NDA resubmission update

Apr 26

Auditors Have Doubts About Zosano Pharma (NASDAQ:ZSAN)

Mar 15

Zosano Pharma up 21% following FDA feedback on Qtrypta application; presents Qtrypta data in migraine

Feb 01

Zosano Pharma requests FDA meeting for its Qtrypta application

Jan 04

Zosano Pharma EPS misses by $0.01

Nov 13

주주 수익률

	ZSAN.Q	US Medical Equipment	US 마켓
7D	40.0%	-1.1%	0.6%
1Y	-100.0%	19.7%	32.1%

수익률 대 산업: ZSAN.Q underperformed the US Medical Equipment industry which returned -22.2% over the past year.

수익률 대 시장: ZSAN.Q underperformed the US Market which returned -20.2% over the past year.

가격 변동성

Is ZSAN.Q's price volatile compared to industry and market?
ZSAN.Q volatility
ZSAN.Q Average Weekly Movement	4,827.6%
Medical Equipment Industry Average Movement	8.7%
Market Average Movement	6.4%
10% most volatile stocks in US Market	14.9%
10% least volatile stocks in US Market	3.2%

안정적인 주가: ZSAN.Q's share price has been volatile over the past 3 months.

시간에 따른 변동성: ZSAN.Q's weekly volatility has increased from 2395% to 4789% over the past year.

회사 소개

설립	직원	CEO	웹사이트
2006	40	Steven Lo	www.zosanopharma.com

Zosano Pharma Corporation 기본 사항 요약

Zosano Pharma 의 수익과 매출은 시가총액과 어떻게 비교하나요?
ZSAN.Q 기본 통계
시가총액	US$3.43k
수익(TTM)	-US$55.19m
수익(TTM)	US$659.00k

0.0x

P/S 비율

0.0x

P/E 비율

ZSAN.Q 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
ZSAN.Q 손익 계산서(TTM)
수익	US$659.00k
수익 비용	US$20.85m
총 이익	-US$20.19m
기타 비용	US$35.01m
수익	-US$55.19m

최근 보고된 수익

Mar 31, 2022

다음 수익 날짜

n/a

주당 순이익(EPS)	-11.26
총 마진	-3,063.13%
순이익 마진	-8,375.11%
부채/자본 비율	0%

ZSAN.Q 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

This company is no longer active

ZSAN.Q 주식 개요

보상

위험 분석

Zosano Pharma Corporation 경쟁사

OTCPK:LHDX.Q

US$4.2k

OTCPK:VIVE

US$1.1k

OTCPK:VRAY.Q

US$18.3k

OTCPK:ABMC

US$4.8k

가격 내역 및 성능

최근 뉴스 및 업데이트

Emergex USA Corporation completed the acquisition of Substantially all assets of Zosano Pharma Corporation for $1 million.

Emergex USA Corp. agreed to acquire Substantially all assets of Zosano Pharma Corporation (OTCPK:ZSAN.Q) for $1.3 million.

Motion for Case Conversion Filed for Zosano Pharma Corporation

Motion for Asset Sale Filed by Zosano Pharma Corporation

Zosano Pharma Corporation to Delist from Nasdaq

Zosano Pharma Corporation Filed for Bankruptcy

Recent updates

Emergex USA Corporation completed the acquisition of Substantially all assets of Zosano Pharma Corporation for $1 million.

Emergex USA Corp. agreed to acquire Substantially all assets of Zosano Pharma Corporation (OTCPK:ZSAN.Q) for $1.3 million.

Motion for Case Conversion Filed for Zosano Pharma Corporation

Motion for Asset Sale Filed by Zosano Pharma Corporation

Zosano Pharma Corporation to Delist from Nasdaq

Zosano Pharma Corporation Filed for Bankruptcy

Joseph “Jay” P. Hagan Resigns as Director of the Board of Directors of Zosano Pharma Corporation

Zosano Pharma Corporation Reports Impairment Charges for the First Quarter Ended March 31, 2022

Consensus forecasts updated

Steven A. Elms Tenders His Resignation as Director of the Board of Directors of Zosano Pharma Corporation

Price target decreased to US$21.00

Consensus revenue estimates increase by 95%

Zosano Pharma Corporation Receives a Response Letter from the U.S. Food and Drug Administration with Regard to the Company’s January 18, 2022 Resubmission of the 505(b)(2) New Drug Application for M207

Zosano Pharma Corporation has completed a Composite Units Offering in the amount of $15.375 million.

Zosano Pharma Corporation has completed a Composite Units Offering.

Zosano Pharma Corporation Resubmits its M207 (Zolmitriptan Transdermal Microneedle System) 505(B)(2) New Drug Application to the U.S. Food and Drug Administration

Zosano Pharma Announces Publication of Clinical Data Demonstrating Comparable Immunogenicity of A Trivalent Influenza Vaccine Formulated on Its Transdermal Microneedle System Versus an Intramuscular Injection of the Vaccine At A Higher Dose

Can Zosano Pharma (NASDAQ:ZSAN) Afford To Invest In Growth?

Is Zosano Pharma (NASDAQ:ZSAN) Weighed On By Its Debt Load?

Consensus forecasts updated

Consensus revenue estimates increase to US$2.08m

Zosano Pharma Corporation Announces Publication of Clinical Data Regarding the Long-Term Use of Qtrypta for the Treatment of Acute Migraine in the Journal of Headache and Pain

Data supports long-term benefit of Zosano's migraine candidate; shares surge 23%

Consensus forecasts updated

Zosano Pharma: Early PK+Safety Study In Q3 2021 May Breathe New Life Into This Biotech

Zosano Pharma Confirms Plan to Move Forward with Pharmacokinetic Study Following Protocol Review by FDA

Zosano shares rise on migraine treatment NDA resubmission update

Consensus revenue estimates increase to US$5.17m

Auditors Have Doubts About Zosano Pharma (NASDAQ:ZSAN)

Earnings miss expectations

Zosano Pharma Corporation Announces John Walker, Chairman of the Board of Directors to Retire from the Board

Zosano Pharma Confirms NDA Resubmission Strategy Following Type A Meeting Minutes from FDA

New 90-day high: US$1.93

Zosano Pharma Corporation Announces NDA Resubmission Plans Following Type A Meeting with FDA

Zosano Pharma up 21% following FDA feedback on Qtrypta application; presents Qtrypta data in migraine

New 90-day high: US$0.81

Zosano Pharma Requests Type A Meeting with the Fda to Review Resubmission Plans for Qtrypta™ New Drug Application

Zosano Pharma requests FDA meeting for its Qtrypta application

Bragar Eagel & Squire, P.C. Reminds Investors of Class Action Lawsuit Filed Against Zosano Pharma Corporation

Pomerantz LLP Reminds Shareholders with Losses on Their Investment in Zosano Pharma Corporation of Class Action Lawsuit and Upcoming Deadline

Zosano Pharma EPS misses by $0.01

New 90-day low: US$0.36

Rosen Announces Filing of Securities Class Action Lawsuit Against Zosano Pharma Corporation

Price target lowered to US$2.00

New 90-day low: US$0.64

New 90-day low: US$0.70

Zosano Pharma Corporation Receives Discipline Review Letter from the U.S. Food and Drug Administration in Connection with the Qtrypta

Zosano Pharma Corporation has completed a Follow-on Equity Offering in the amount of $20.782018 million.

New 90-day high - US$1.69

New 90-day high - US$1.22

Zosano Pharma Corporation(NasdaqCM:ZSAN) dropped from Russell Microcap Growth Index

주주 수익률

가격 변동성

회사 소개

Zosano Pharma Corporation 기본 사항 요약

0.0x

0.0x

수익 및 수익